Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 2/20 | 1.00 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | BMX | P51813 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 1.00 |
| ▸ | CTSC | P53634 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | ITK | Q08881 | 1/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 1/20 | 1.00 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 1.00 |
| ▸ | EML4 | Q9HC35 | 1/20 | 1.00 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93699 | 1.00 | EGFR (1.00) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL29733655 | 1.00 | EGFR (1.00) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL1706773 | 0.99 | EGFR (0.97) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL10127856 | 0.94 | EGFR (0.88) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL9945457 | 0.94 | EGFR (0.91) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL9945476 | 0.93 | EGFR (0.88) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL10128056 | 0.93 | EGFR (0.87) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL19705782 | 0.93 | EGFR (0.87) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL4176137 | 0.93 | EGFR (1.00) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL4164770 | 0.93 | EGFR (1.00) | EGFRNUAK1NUAK2JAK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4724151-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724150-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12595297-B2 | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors | IN3BIO LTD. (BM) | 2026-04-07 | — | — | US | claimed |
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | claimed |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250275978-A1 | USE OF ONVANSERTIB AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | CARDIFF ONCOLOGY, INC. | 2025-09-04 | — | — | US | claimed |
| WO-2025137424-A1 | SOLID FORMS OF AN ERBB INHIBITOR | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2022072632-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022072645-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| CN-114206342-A | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| EP-3965896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The United States Government as Represented by the Department of Veterans Affairs (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2022045976-A1 | METHOD OF MODULATING SENSITIVITY TO TYROSINE KINASE INHIBITOR | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2022-03-03 | — | — | WO | claimed |
| US-20220041704-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | IN3BIO LTD. (BM) | 2022-02-10 | — | — | US | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595297-B2 | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors | EGFR, ERBB2, ERBB3 | EGFR 1/4885NUAK1 942/4885NUAK2 871/4885 |
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | PLK1, BRAF, KRAS | EGFR 6/4885NUAK1 987/4885NUAK2 816/4885 |
| US-20250275978-A1 | USE OF ONVANSERTIB AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | KRAS, PLK1, NRAS | EGFR 10/4885NUAK1 539/4885NUAK2 449/4885 |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | MICA, CD74, HLA-DRB1 | EGFR 2295/4885NUAK1 3805/4885NUAK2 3894/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | EGFR 324/4885NUAK1 1161/4885NUAK2 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.